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Abstract Hyperuricemia is associated with the progres-
sion of chronic kidney disease (CKD) and cardiovascular
diseases. Topiroxostat, a selective xanthine oxidase inhi-
bitor, effectively reduces serum uric acid (UA) levels and
urinary albumin excretion (UAE) in CKD patients. A
50-year-old Japanese man was referred to our hospital due
to albuminuria and hyperuricemia, and renal biopsy
showed a typical hyperuricemic arteriolopathy. Treatment
with topiroxostat decreased serum UA levels (9.2 mg/dL at
baseline to 6.4 mg/dL after 6 months), UAE (388 to
88 mg/g.cr), and urinary level of liver-type fatty acid-
binding protein (28.8 to 19.8 lg/g.cr). Interestingly,
topiroxostat treatment was associated with a trend towards
improved flow-mediated dilation (5.4 to 5.8%). These
results suggested that topiroxostat in CKD patients with
hyperuricemia is potentially effective, not only for ame-
liorating renal damages but also for improving endothelial
function beyond its UA-lowering action.
Key Points
In the present case report, topiroxostat treatment in
hyperuricemic patients with renal arteriolopathy
reduced renal damage and increased flow-mediated
dilation value.
Further studies are needed to assess the protective
effects of topiroxostat treatment on renal and
endothelial function in hyperuricemic patients.
1 Introduction
Elevated levels of serum uric acid (UA) are closely asso-
ciated with an increased risk for mortality in patients with
chronic kidney disease (CKD) [1]. Hyperuricemia has been
shown to be a significant and independent risk factor for
the development of kidney disease and albuminuria in the
general Japanese population [2], and an animal study
suggested that hyperuricemia may cause progression of
hypertension and CKD by inducing pre-glomerular arteri-
olar damage, characterized by hyalinosis, wall thickening,
and an increased number of smooth muscle cells [3].
Injuries to pre-glomerular arterioles cause glomerular
hypertension and ischemia, which are universal risk factors
for the progression of renal damage [3, 4]. A study of renal
biopsies collected from hyperuricemic patients suggested
that high levels of serum UA may be associated with the
development of renal arteriolopathy and may play a pivotal
role in the progression of renal injuries [5].
There are some evidence that UA-lowering treatment is
effective for delaying the progression of CKD associated
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with hyperuricemia [6]. In studies of db/db mice, topirox-
ostat, a selective xanthine oxidase (XO) inhibitor, caused a
dose-dependent decrease in both urinary albumin excretion
(UAE) and plasma XO activity; however, in contrast,
another XO inhibitor, febuxostat, showed no such effect
[7]. In addition, topiroxostat 160 mg was reported to
effectively and safely decrease serum UA levels and UAE
in hyperuricemic patients with stage III CKD [8]. Taken
together, these results suggest topiroxostat may have a
renal protective effect over and above its UA-lowering
action. In the present report, we describe a patient with
renal biopsy-proven hyperuricemic arteriolopathy in whom
topiroxostat reduced not only UAE but also urinary liver-
type fatty acid-binding protein (L-FABP), a marker of
tubulointerstitial injury, and flow-mediated dilation (FMD),
a marker of endothelial dysfunction.
2 Case Presentation
A 50-year-old Japanese male was referred to our hospital
due to albuminuria and hyperuricemia. At 40 years of age,
the patient had been diagnosed with hyperuricemia
(8.4 mg/dL) in another clinic but did not receive follow-up
treatment at that time. Then, at 50 years of age, he visited
the same clinic and was again diagnosed with hyper-
uricemia (9.0 mg/dl) and high UAE (390 mg/g.cr), leading
to admission to our hospital for a detailed examination of
CKD. He had no history of smoking or major diseases,
excluding hyperuricemia, and no family history of renal
diseases. Clinical examination and laboratory tests at
admission showed the following characteristics: height
170 cm, weight 68 kg, blood pressure 130/82 mmHg, heart
rate 70 beats/min, serum UA 9.2 mg/dL, UAE 388.6 mg/
g.cr, urinary L-FABP 28.8 lg/g.cr (normal range\8.4 lg/
g.cr), serum creatinine 1.32 mg/dL, estimated glomerular
filtration ratio 46.6 mL/min/1.73 m2, no hematuria, normal
proteinemia (serum total protein 7.0 g/dL, serum albumin
4.2 g/dL), normoglycemia (fasting blood sugar 96 mg/dL,
HbA1c 5.6%), and normal lipid profile (low-density
lipoprotein cholesterol 126 mg/dL, triglycerides 96 mg/dL,
high-density lipoprotein cholesterol 66 mg/dL). Plasma
serology was negative for antinuclear antibody,
antiglomerular basement membrane antibody, myeloper-
oxidase antineutrophil cytoplasmic antibody (ANCA),
proteinase 3-ANCA, hepatitis C antibody, and hepatic B
antigen. Serum complement and immunoglobulin levels
were within normal limits, and the FMD value was 5.4%
(normal range[6.0%).
A renal biopsy was performed on day 3 after admission.
Renal histopathology showed renal arteriolar hyalinosis
and arteriolar wall thickening, tubular atrophy, and inter-
stitial fibrosis, but only minor changes in the glomeruli
(Fig. 1). These findings were compatible with renal arte-
riolopathy related to hyperuricemia [5]. In addition,
immunohistochemistry for deposition of immunoglobu-
lin G (IgG), IgM, IgA, C3, and C1q were all negative. The
patient was therefore diagnosed with hyperuricemic arte-
riolopathy. Because of its potential renal protective effect
described earlier, topiroxostat treatment (160 mg/day) was
initiated on day 7. The serial changes in laboratory data
pre- and post-topiroxostat treatment are shown in Table 1.
The patient’s serum UA level decreased from 9.2 to
7.4 mg/dL after 3 months and 6.4 mg/dL after 6 months,
while UAE decreased from 388.6 to 288.2 mg/g.cr after
3 months and 88.4 mg/g.cr after 6 months. The urinary
L-FABP level also decreased from 28.8 to 24.2 lg/g.cr
after 3 months and 19.8 lg/g.cr after 6 months. In addi-
tion, FMD increased slightly from 5.4 to 5.6% after
3 months and 5.8% after 6 months. Other parameters,
including blood pressure, renal function, and lipid profile,
showed only minor changes during the 6-month treatment
period. No adverse drug reaction was observed.
3 Discussion
The present case of hyperuricemia and biopsy-proven renal
arteriolar injury is the first to demonstrate that treatment
with topiroxostat has the ability to decrease serum UA,
UAE, and urinary L-FABP levels, and increase FMD
value.
Hyperuricemia is strongly associated with a wide range
of complications, such as hypertension, metabolic syn-
drome, cardiovascular disease, and CKD [9–13]. UA-
lowering therapy is therefore important to prevent or delay
the progression of these diseases. Previous experimental
animal studies demonstrated that hyperuricemia could
cause progression of CKD by inducing pre-glomerular
arteriolar damages, characterized by hyalinosis and wall
thickening [3, 4]. Kohagura et al. [5] reported an associa-
tion between UA levels in hyperuricemic CKD patients and
parameters of renal arteriolopathy, such as hyalinosis and
wall thickening. It is suggested that the association between
hyperuricemia and renal arteriolar damages could poten-
tially induce glomerular hypertension and resultant pro-
gression of CKD [5, 14]. It would therefore be anticipated
that UA-lowering therapy should slow the progression of
CKD and improve renal outcomes in patients with hyper-
uricemia and CKD [15]. Topiroxostat is a non-purine
selective XO inhibitor approved in Japan as a UA-lowering
agent [16]. High doses of topiroxostat (160 mg/day) were
shown to reduce UAE and serum UA levels compared with
placebo in patients with hyperuricemia and stage III CKD
with or without gout [8]. It was also recently reported that
urinary excretion of L-FABP was significantly lower in an
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animal model of adenine-induced renal injury treated with
topiroxostat compared with animals treated with febuxostat
[17]. Urinary L-FABP is approved as a clinical biomarker
of tubular damage and may be a useful prognostic bio-
marker of progression to end-stage renal disease and the
onset of cardiovascular disease in patients with CKD [18].
On the basis of these results, in the present case we decided
to administer topiroxostat 160 mg/day, but not febuxostat.
A previous study provided an interesting insight in that
an excess level of UA may have a direct effect on the cells
that determine the structure of vessels [5]. In this regard,
UA has been shown to promote proliferation of vascular
smooth muscle cells and reduce nitric oxide, resulting in
endothelial dysfunction [19]. On the other hand, Chen et al.
[20] reported an interrelationship between multiple mark-
ers and pathways, leading to impaired endothelial function
in patients with CKD. Given these relationships, there
seems to be a pathological triangle between hyperuricemia,
CKD, and endothelial dysfunction. However, some recent
studies have reported conflicting results with decreased
serum UA levels induced by allopurinol, a conventional
XO inhibitor, increasing FMD in patients with stage II–IV
CKD and plasma UA levels[ 5.5 mg/dL [21]. In contrast,
another study showed that allopurinol did not improve
endothelial function in asymptomatic hyperuricemic
patients with stage III CKD [22]. Therefore, it remains
controversial whether UA-lowering therapy improves
endothelial function in hyperuricemic patients with CKD.
Moreover, the precise mechanisms by which XO inhibitors
modulate endothelial function have yet to be elucidated.
The present case of a patient treated with topiroxostat was
the first to show an increase in the FMD value after
6 months of treatment; however, no data regarding whether
there is a dose-dependent effect on endothelial function and
whether XO inhibitors exert as a class effect are currently
available. Recent randomized trials on post cardiac surgery
hyperuricemic patients with or without CKD showed that
febuxostat provided superior anti-inflammatory and reno-
protective effects than allopurinol [23, 24]. A randomized
trial to assess the effect of febuxostat on atherosclerosis
and vascular function over 24 months is currently ongoing
in Japan [25]. Furthermore, the ETUDE study group in
Japan has also started a randomized study to clarify the
renoprotective effect of topiroxostat and evaluate the safety
Fig. 1 Histopathology of kidney specimens. a Vascular wall thickening and interstitial fibrosis are prominent features in the sections (PAS
staining 9200). b Hyalinosis in the afferent arteriole (arrow) (PAS staining 9400). PAS periodic acid–Schiff
Table 1 Serial changes in
laboratory and clinical indices
over the 6-month treatment
period
Variables Pre-treatment After 3 months After 6 months
Systolic/diastolic blood pressure, mmHg 130/82 128/80 128/80
Low-density lipoprotein cholesterol, mg/dL 126 124 122
High-density lipoprotein cholesterol, mg/dL 66 68 66
Triglyceride, mg/dL 98 100 100
Serum creatinine, mg/dL 1.32 1.30 1.28
Blood urea nitrogen, mg/dL 22 22 20
Uric acid, mg/dL 9.2 7.4 6.4
Urinary albumin excretion, mg/g.cr 388.6 288.2 88.4
Liver-type fatty acid-binding protein, lg/g.cr 28.8 24.2 19.8
Flow-mediated dilation, % 5.4 5.6 5.8
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of its serum UA level-lowering effect in patients with
diabetic nephropathy and hyperuricemia [26]. Thus,
increasing attention is being given to the protective effects
of newer XO inhibitors on renal and cardiovascular sys-
tems beyond their UA-lowering action.
4 Conclusions
We report a case of a patient with CKD and biopsy-proven
hyperuricemic-associated arteriolopathy in whom topirox-
ostat treatment was effective in reducing serum UA, UAE,
and urinary L-FABP levels, and in increasing FMD value.
This finding indicates that large-scale and long-term ran-
domized trials are warranted to test the protective effects of
topiroxostat treatment on renal and endothelial function in
hyperuricemic patients.
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